As expected, MS023 treatment dramatically decreased the H4R3me2a level and imatinib reduced the p‐BCR‐ABL level in primary CML CD34+CD38− cells (Figure S1A, Supporting Information). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.